Search

Your search keyword '"Szender, J.B."' showing total 30 results
Start Over Author "Szender, J.B."
30 results on '"Szender, J.B."'

1. Variability in body mass index (BMI) during adjuvant chemotherapy is associated with clinical outcomes among invasive ovarian cancer patients

Author

Starbuck, K., primary, Cannioto, R.A., additional, Etter, J.L., additional, Moysich, K.B., additional, Duncan, W., additional, Morrell, K., additional, Almohanna, H., additional, Joseph, J.M., additional, Szender, J.B., additional, Zsiros, E., additional, Odunsi, K., additional, Frederick, P.J., additional, Lele, S.B., additional, Akers, S.N., additional, and Eng, K.H., additional

Published
2018
Full Text
View/download PDF

7. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium

Author

Minlikeeva, A.N., Freudenheim, J.L., Eng, K.H., Cannioto, R.A., Friel, G., Szender, J.B., Segal, B., Odunsi, K., Mayor, P., Diergaarde, B., Zsiros, E., Kelemen, L.E., Kobel, M., Steed, H., Defazio, A., Jordan, S.J., Fasching, P.A., Beckmann, M.W., Risch, H.A., Rossing, M.A., Doherty, J.A., Chang-Claude, J., Goodman, M.T., Dork, T., Edwards, R., Modugno, F., Ness, R.B., Matsuo, K., Mizuno, M., Karlan, B.Y., Goode, E.L., Kjaer, S.K., Hogdall, E., Schildkraut, J.M., Terry, K.L., Cramer, D.W, Bandera, E.V., Paddock, L.E., Kiemeney, L.A.L.M., Massuger, L.F.A.G., Sutphen, R., Anton-Culver, H., Ziogas, A., Menon, U., Gayther, S.A., Ramus, S.J., Gentry-Maharaj, A., Pearce, C.L., Wu, A.H., Kupryjanczyk, J., Jensen, A., Webb, P.M., Moysich, K.B., Minlikeeva, A.N., Freudenheim, J.L., Eng, K.H., Cannioto, R.A., Friel, G., Szender, J.B., Segal, B., Odunsi, K., Mayor, P., Diergaarde, B., Zsiros, E., Kelemen, L.E., Kobel, M., Steed, H., Defazio, A., Jordan, S.J., Fasching, P.A., Beckmann, M.W., Risch, H.A., Rossing, M.A., Doherty, J.A., Chang-Claude, J., Goodman, M.T., Dork, T., Edwards, R., Modugno, F., Ness, R.B., Matsuo, K., Mizuno, M., Karlan, B.Y., Goode, E.L., Kjaer, S.K., Hogdall, E., Schildkraut, J.M., Terry, K.L., Cramer, D.W, Bandera, E.V., Paddock, L.E., Kiemeney, L.A.L.M., Massuger, L.F.A.G., Sutphen, R., Anton-Culver, H., Ziogas, A., Menon, U., Gayther, S.A., Ramus, S.J., Gentry-Maharaj, A., Pearce, C.L., Wu, A.H., Kupryjanczyk, J., Jensen, A., Webb, P.M., and Moysich, K.B.

Abstract

Contains fulltext : 177359.pdf (publisher's version ) (Closed access), Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced).Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470-3. (c)2017 AACR.

Published
2017

8. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium

Author

Minlikeeva, A.N., Freudenheim, J.L., Cannioto, R.A., Szender, J.B., Eng, K.H., Modugno, F., Ness, R.B., LaMonte, M.J., Friel, G., Segal, B.H., Odunsi, K., Mayor, P., Zsiros, E., Schmalfeldt, B., Klapdor, R., Drk, T., Hillemanns, P., Kelemen, L.E., Kbel, M., Steed, H., Fazio, A. de, Jordan, S.J., Nagle, C.M., Risch, H.A., Rossing, M.A., Doherty, J.A., Goodman, M.T., Edwards, R., Matsuo, K., Mizuno, M., Karlan, B.Y., Kjaer, S.K., Hogdall, E., Jensen, A., Schildkraut, J.M., Terry, K.L., Cramer, D.W, Bandera, E.V., Paddock, L.E., Kiemeney, L.A.L.M., Massuger, L.F.A.G., Kupryjanczyk, J., Berchuck, A., Chang-Claude, J., Diergaarde, B., Webb, P.M., Moysich, K.B., Minlikeeva, A.N., Freudenheim, J.L., Cannioto, R.A., Szender, J.B., Eng, K.H., Modugno, F., Ness, R.B., LaMonte, M.J., Friel, G., Segal, B.H., Odunsi, K., Mayor, P., Zsiros, E., Schmalfeldt, B., Klapdor, R., Drk, T., Hillemanns, P., Kelemen, L.E., Kbel, M., Steed, H., Fazio, A. de, Jordan, S.J., Nagle, C.M., Risch, H.A., Rossing, M.A., Doherty, J.A., Goodman, M.T., Edwards, R., Matsuo, K., Mizuno, M., Karlan, B.Y., Kjaer, S.K., Hogdall, E., Jensen, A., Schildkraut, J.M., Terry, K.L., Cramer, D.W, Bandera, E.V., Paddock, L.E., Kiemeney, L.A.L.M., Massuger, L.F.A.G., Kupryjanczyk, J., Berchuck, A., Chang-Claude, J., Diergaarde, B., Webb, P.M., and Moysich, K.B.

Abstract

Contains fulltext : 174140.pdf (publisher's version ) (Closed access), PURPOSE: Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype. METHODS: Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes. RESULTS: History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94. CONCLUSIONS: Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidi

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results